Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | EBP | Q15125 | 1/20 | 0.58 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19392346 | 0.81 | KMT2A (0.76) | KMT2AMEN1NPSR1L3MBTL1MAPT | |
| SCHEMBL7024483 | 0.80 | KMT2A (0.73) | KMT2AMEN1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL31212435 | 0.77 | EBP (0.70) | KMT2AMEN1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL31212431 | 0.77 | EBP (0.70) | KMT2AMEN1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL27565870 | 0.77 | KMT2A (0.61) | KMT2AMEN1ALDH1A1HTR1AHTR2A | |
| SCHEMBL5746621 | 0.75 | KMT2A (0.65) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7030304 | 0.75 | KMT2A (0.74) | KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL5749729 | 0.74 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPK1NPSR1 | |
| SCHEMBL19823068 | 0.74 | EBP (0.74) | ALDH1A1NPSR1EBPDHCR7EPHX2 | |
| SCHEMBL7023315 | 0.74 | KMT2A (0.78) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | KMT2A 472/4885MEN1 3253/4885ALDH1A1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.